left-arrow right-arrow pinterest facebook google_plus linkedin

Alliance A021502


Recruiting | Phase III 

Official Title:

Testing the Addition of the Antibody Atezolizumab to Usual Chemotherapy after Surgery in Patients with Colon Cancer

Study Purpose:

The purpose of this study is to compare any good and bad effects of using the drug atezolizumab along with the usual chemotherapy compared to the usual chemotherapy alone.


  • Group 1: Chemotherapy plus atezolizumab for 6 months, then atezolizumab alone for 6 months

  • Group 2: Chemotherapy for 6 months

  • Quality of Life surveys

  • After completion of the study patients will be followed for 8 years

Key Participation Requirements: 


Male or Female


19 years and older


Stage III Colon cancer


Stage III colon cancer that has been removed by surgery.

Patients must sign an approved informed consent and authorization permitting release of personal health information.

Methodist Health System Trial Code:

Alliance A021502

For more information, visit the U.S. National Library of Medicine clinical trial database

To learn more about this clinical trial please contact us today!